Indications: Silymarin is indicated as adjunctive therapy in the
treatment of liver disease of varying etiologies; acute hepatitis, chronic
persistent and chronic aggressive hepatitis, cirrhosis of the liver, fatty
liver, toxic metabolic or toxic metabolic liver damage. It has been shown to
protect the liver from damage caused by general anesthesia.
Unless otherwise specified,
all product names appearing in this Internet site are trademarks
owned by or licensed to Abbott Laboratories, its subsidiaries or
affiliates. No use of any Abbott trademark, trade name, or trade
dress in this site may be made without the prior written
authorization of Abbott Laboratories, except to identify the
product or services of the company.